Curis (CRIS) Retained Earnings (2010 - 2026)
Curis' (CRIS) quarterly Retained Earnings came in at -$1.3 billion in Q1 2026, down 1.69% YoY from -$1.3 billion in Q1 2025, and down 1.94% on a QoQ basis from -$1.2 billion in Q4 2025.
Curis (CRIS) Retained Earnings (2010 - 2026) Analysis & Trends
Curis (CRIS) has 17 years of Retained Earnings data on file, last reported at -$1.3 billion in Q1 2026.
- Quarterly Retained Earnings fell 1.69% year-over-year to -$1.3 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.3 billion (down 1.69% YoY) and the FY2025 annual result came in at -$1.2 billion, down 0.61% from the prior year.
- Retained Earnings slipped to -$1.3 billion in Q1 2026, from -$1.2 billion in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $229000.0 in Q4 2023 to a low of -$1.3 billion in Q3 2025.
- A 5-year average of -$1.1 billion and a median of -$1.2 billion in 2023 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2023 — Retained Earnings jumped 100.02% — and 2024, when it sank 1194450.49%.
- Tracing CRIS's Retained Earnings over 5 years: stood at -$1.1 billion in 2022, then surged by 100.02% to $229000.0 in 2023, then sank by 541496.94% to -$1.2 billion in 2024, then retreated by 0.61% to -$1.2 billion in 2025, then dropped by 1.94% to -$1.3 billion in 2026.
- The last three Retained Earnings figures came in at -$1.3 billion (Q1 2026), -$1.2 billion (Q4 2025), and -$1.3 billion (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -6.33 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 6.57 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 4.38 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 20.91 Bn |
| 10 | Curis | 3.44 Mn | -2.18 Mn | - | -1.30 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.27 Bn |
| Dec 31, 2025 | -1.25 Bn |
| Sep 30, 2025 | -1.30 Bn |
| Jun 30, 2025 | -1.26 Bn |
| Mar 31, 2025 | -1.25 Bn |
| Dec 31, 2024 | -1.24 Bn |
| Sep 30, 2024 | -1.23 Bn |
| Jun 30, 2024 | -1.20 Bn |
| Mar 31, 2024 | -1.20 Bn |
| Dec 31, 2023 | 229,000.00 |
| Sep 30, 2023 | 103,000.00 |
| Jun 30, 2023 | -1.20 Bn |
| Mar 31, 2023 | -1.20 Bn |
| Dec 31, 2022 | -1.15 Bn |
| Sep 30, 2022 | -1.10 Bn |
| Jun 30, 2022 | -1.12 Bn |
| Mar 31, 2022 | -1.11 Bn |
| Dec 31, 2021 | -109,000.00 |
| Sep 30, 2021 | -1.10 Bn |
| Jun 30, 2021 | -1.07 Bn |